Akums introduces Hydroxyurea oral suspension for sickle cell disease
Akums gets DCGI nod for triple combination diabetes medication
This approval allows Perampanel Oral Suspension to serve as adjunctive therapy for treatment of partial-onset seizures (POS) with or without secondarily generalised seizures, as well as primary generalised tonic-clonic (PGTC) seizures in patients with epilepsy aged 12 years and older
Akums Drugs & Pharmaceuticals on Thursday said it has forayed into the gummies segment by setting up a new manufacturing plant. The company said it aims to cater to a host of conditions for adults, paediatrics and geriatric population who are looking for an alternative to conventional dosage forms like tablets, capsules, syrup etc, who no longer find these options palatable or convenient.
Akums, Lyrus Life Sciences collaborate for patented technologies and formulations
Akums receives DCGI approval for type 2 diabetes drug to improve insulin resistance
Akums enters into a joint association with Leiutis and Biophore for introducing first-of-its-kind therapeutics
Akums, Microcore Research enter JV to develop NESM dietary supplements
Glaxosmithkline Pharmaceuticals NSE -0.46 % has issued cease and desist notices to Akums Drugs and Pharmaceuticals (ADPL) and its associate Nicholas Healthcare, demanding to stop selling ranitidine under brand name ‘Zintac’, alleging that it’s an infringement of its trademark ‘Zinetac’.